{"url_path":"/sec/crbp/8-k/2026-05-21/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1595097/0001193125-26-233507-index.html","accession_number":"0001193125-26-233507","cik":"0001595097","ticker":"CRBP","issuer_name":"Corbus Pharmaceuticals Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1595097/0001193125-26-233507-index.html","primary_entity_key":"0001595097","primary_entity_name":"Corbus Pharmaceuticals Holdings, Inc."},"word_count":200,"has_tables":true,"body_markdown":"Item 9.01 Financial Statements and Exhibits.\n\n(d) Exhibits:\n\nExhibit No.\n\nDescription\n\n10.1\n\n[Employment Agreement, dated May 21, 2026, between Corbus Pharmaceuticals Holdings, Inc. and Nishant Saxena.](crbp-ex10_1.htm)\n\n10.2\n\n \n\n[Form of Incentive Stock Option Grant Agreement (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 20, 2024).](https://www.sec.gov/Archives/edgar/data/1595097/000095017024062436/crbp-ex10_2.htm)\n\n10.3\n\n \n\n[Form of Non-Statutory Stock Option Grant Agreement (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 20, 2024).](https://www.sec.gov/Archives/edgar/data/1595097/000095017024062436/crbp-ex10_3.htm)\n\n10.4\n\n \n\n[Form of Restricted Stock Unit Award Agreement (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 20, 2024).](https://www.sec.gov/Archives/edgar/data/1595097/000095017024062436/crbp-ex10_5.htm)\n\n99.1\n\n \n\n[Press Release issued by Corbus Pharmaceuticals Holdings, Inc. dated May 21, 2026.](crbp-ex99_1.htm)\n\n104\n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nCorbus Pharmaceuticals Holdings, Inc.\n\nDate:\n\nMay 21, 2026\n\nBy:\n\n/s/ Yuval Cohen\n\nName: Yuval Cohen\nTitle: Chief Executive Officer"}